Eris Lifesciences board to weigh equity issue for acquisition funding

Eris Lifesciences Limited has announced a Board of Directors meeting for Monday, November 24, 2025. The primary agenda includes considering a proposal for the issuance of equity shares through a preferential issue for non-cash consideration. This issuance is intended to finance the acquisition of the remaining 30% equity stake in Swiss Parenterals Limited.

The proposed preferential issue and acquisition are subject to approval from the company's members and other necessary regulatory and statutory clearances. The board will also discuss convening an extra-ordinary general meeting or initiating a postal ballot process to secure shareholder approval for the preferential issue.